04:32 AM EDT, 08/04/2026 (MT Newswires) -- Photocure (PHO.OL) plans to "vigorously pursue full payment" of a milestone fee from Asieris Pharmaceuticals despite the latter's rejection and counterclaim. The Norwegian diagnostic company said Tuesday that Asieris on Monday denied its $11 million arbitration demand and also filed a counterclaim for the return of the $6.6 million it paid in April. Photocure maintained that Asieris should have paid the full $11 million milestone payment when China's National Medical Products Administration approved the commercial launch of Cevira in March under the terms of their license agreement.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.